Skip to main content

Table 1 Ongoing phase 2/3 controlled trials investigating PARP inhibitors in mCRPC

From: Novel therapies are changing treatment paradigms in metastatic prostate cancer

Trial name

Intervention

Control

DNA repair mutation required

Prior treatment for mCRPC allowed

Estimated enrollment (patients)

Trial phase

Clinicaltrials.gov identifier

BRCAAway

Olaparib or olaparib/AAP

AAP

Yes

No

70

2

NCT03012321

PROpel

Olaparib/AAP

AAP

No

No

720

3

NCT03732820

COMRADE

Olaparib/Ra 223

Ra 223

No

Yes

112

1/2

NCT03317392

KEYLYNK-010

Olaparib/pembrolizumab

AAP or enzalutamide

No

Yes

780

3

NCT03834519

KEYNOTE-365

Olaparib/pembrolizumab

Pembrolizumab + one of docetaxel, enzalutamide, or AAP

No

Yes

400

1b/2

NCT02861573

TRITON3

Rucaparib

AAP or enzalutamide or docetaxel

Yes

No

400

3

NCT02975934

N/A

Rucaparib or rucaparib/nivolumab

Nivolumab

No

No

60

1b/2

NCT03572478

CheckMate 9KD

Rucaparib/nivolumab

Nivolumab + enzalutamide or docetaxel

No

Yes

330

2

NCT03338790

MAGNITUDE

Niraparib/AAP

AAP

No

No

1000

3

NCT03748641

TALAPRO-2

Talazoparib/enzalutamide

Enzalutamide

No

No

1037

3

NCT03395197

  1. mCRPC: metastatic castration-resistant prostate cancer; AAP: abiraterone and prednisone; Ra 223: radium 223 dichloride; VEGF: vascular endothelial growth factor